These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35181842)

  • 1. Potential Future Drug Development Lag in Japan Based on an Analysis of Multiregional Clinical Trials in the US, Europe, and East Asia.
    Noguchi A; Hanaoka H; Uyama Y
    Ther Innov Regul Sci; 2022 May; 56(3):523-529. PubMed ID: 35181842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploratory Analysis of Drug Lag in New Oncology Drugs Between Japan and the US.
    Maki A; Narukawa M
    Ther Innov Regul Sci; 2023 Jul; 57(4):671-677. PubMed ID: 36966205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of global versus Asian clinical trial strategies supportive of registration of drugs in Japan.
    Shirotani M; Kurokawa T; Chiba K
    J Clin Pharmacol; 2014 Jul; 54(7):753-64. PubMed ID: 24496890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of Asian Participation in Multi-regional Clinical Trials Reviewed for Drug Approval in Japan: Opportunities for Collaboration Between South-East Asia, East Asia, and Japan.
    Aoi Y; Kato Y; Asano K; Otsubo Y; Uyama Y
    Ther Innov Regul Sci; 2023 Nov; 57(6):1298-1303. PubMed ID: 37587270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
    Tsuji K; Tsutani K
    J Clin Pharm Ther; 2010 Jun; 35(3):289-301. PubMed ID: 20848767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Drug Lags in Development Initiation, New Drug Application and Approval Between Japan and the USA and the Impact of Local Versus Multi-regional Clinical Trials.
    Ushijima S; Matsumaru N; Tsukamoto K
    Pharmaceut Med; 2021 Jul; 35(4):253-260. PubMed ID: 34291425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different Development Strategies Affecting Japan's Drug lag between Japan-Based and Foreign-Based Companies.
    Hidaka M; Hanaoka H; Uyama Y
    Ther Innov Regul Sci; 2024 Jul; 58(4):714-720. PubMed ID: 38575785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Regulatory Reforms in China on Drug Lag: The Role of Clinical Development Strategies.
    Han Y; Jiang R; Li J; Wang Y; Shao R; Xie J
    Clin Pharmacol Ther; 2024 Jun; 115(6):1400-1407. PubMed ID: 38429944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan.
    Rokuda M; Matsumaru N; Tsukamoto K
    Clin Ther; 2018 Feb; 40(2):284-295. PubMed ID: 29361305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Pediatric Drug Approval Lag in Japan.
    Ueyama E; Kaneko M; Narukawa M
    Ther Innov Regul Sci; 2021 Mar; 55(2):336-345. PubMed ID: 32959206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The notorious "drug lag" for oncology drugs in Japan.
    Yonemori K; Hirakawa A; Ando M; Hirata T; Yunokawa M; Shimizu C; Katsumata N; Tamura K; Fujiwara Y
    Invest New Drugs; 2011 Aug; 29(4):706-12. PubMed ID: 21286780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncology drug lag in Japan: has it improved over the last decade?
    Tachibana Y; Narukawa M
    Int J Clin Oncol; 2023 Nov; 28(11):1451-1460. PubMed ID: 37561368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The necessary conduct: Exploratory multiregional clinical trials in East Asia.
    Jeon I; Kim YK; Song I; Yoon DY; Huh KY; Jin X; Yu KS; Lee S; Kumagai Y; Jang IJ
    Clin Transl Sci; 2021 Nov; 14(6):2399-2407. PubMed ID: 34397152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004-2018).
    Konwar M; Maurya MR; Nishandar TB; Thatte UM; Gogtay NJ
    Perspect Clin Res; 2021; 12(3):159-164. PubMed ID: 34386381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.
    Zhou X; Friedlander S; Kupperman E; Sedarati F; Kuroda S; Hua Z; Yuan Y; Yamamoto Y; Faller DV; Haikawa K; Nakai K; Bowen S; Dai Y; Venkatakrishnan K
    Clin Transl Sci; 2021 May; 14(3):1069-1081. PubMed ID: 33503305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations.
    Tsuji K; Tsutani K
    Eur J Pharm Biopharm; 2008 Mar; 68(3):496-502. PubMed ID: 17884403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Associated with Inclusion of Japan in Phase I Multiregional Clinical Trials in Oncology.
    Maki A; Narukawa M
    Ther Innov Regul Sci; 2024 Jul; 58(4):766-772. PubMed ID: 38652349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug approval delays in hematologic malignancies between Europe and the US and between Japan and the US: a clinical perspective.
    Matsuda K; Nagai S; Sugimoto K
    Jpn J Clin Oncol; 2023 Dec; 53(12):1125-1129. PubMed ID: 37642224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
    Kawabata-Shoda E; Masuda S; Kimura H
    J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International oncology drug approvals for multiregional or single-country clinical trials: A systematic review.
    Zhang M; Onakpoya I; Rupalla K
    Front Med (Lausanne); 2022; 9():1084980. PubMed ID: 36590932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.